By Caroline Humer WASHINGTON (Reuters) - The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put unprecedented pressure on global pharmaceutical makers to lower prices for its clients. The comments by CVS Health Chief Medical Officer Troyen Brennan suggest U.S. drug benefit managers will be pressing for much steeper discounts on new biosimilar drugs than the 20 percent to 30 percent widely expected by Wall Street. Depending on how similar treatments are, and on demand from doctors and patients, biosimilar pricing could more closely track the face-off among branded drugs, Brennan said in an interview on Wednesday. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment